Top Page
Sleep Cycle AB
(SLEEP)
Sleep Cycle AB (SLEEP) vs. iShares MSCI Sweden ETF (EWD)
Sleep Cycle AB Business Overview & Revenue Model
Sleep Cycle AB Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 247.88M | 261.53M | 236.15M | 213.27M | 182.94M |
| Gross Profit | 121.36M | 201.87M | 128.55M | 156.65M | 141.62M |
| EBITDA | 73.62M | 88.45M | 64.05M | 46.27M | 12.37M |
| Net Income | 53.21M | 62.64M | 46.14M | 33.94M | 8.11M |
Balance Sheet | |||||
| Total Assets | 200.15M | 236.49M | 230.54M | 301.37M | 227.76M |
| Cash, Cash Equivalents and Short-Term Investments | 120.85M | 144.82M | 133.47M | 232.86M | 165.51M |
| Total Debt | 7.38M | 11.74M | 15.92M | 4.20M | 2.49M |
| Total Liabilities | 128.31M | 157.04M | 169.55M | 140.54M | 118.86M |
| Stockholders Equity | 71.83M | 79.46M | 61.00M | 160.83M | 108.90M |
Cash Flow | |||||
| Free Cash Flow | 52.88M | 59.73M | 51.00M | 53.76M | 14.15M |
| Operating Cash Flow | 52.93M | 63.66M | 52.72M | 61.53M | 20.09M |
| Investing Cash Flow | -13.15M | -3.92M | -6.81M | -7.77M | -5.93M |
| Financing Cash Flow | -64.19M | -48.36M | -145.30M | 14.01M | 98.22M |
Sleep Cycle AB Technical Analysis
Sleep Cycle AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr462.79M | 14.91 | ― | 3.48% | ― | ― | |
69 Neutral | kr337.01M | 6.33 | 96.69% | 7.64% | 0.29% | 6.80% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
52 Neutral | kr57.60M | 26.39 | ― | ― | ― | ― | |
47 Neutral | kr108.64M | -0.84 | ― | ― | ― | ― | |
43 Neutral | kr71.73M | -0.55 | -10.28% | ― | -18.26% | -109.47% |
Sleep Cycle AB Corporate Events
Sleep Cycle’s 2025 year-end report shows a tightened focus on SDK licensing and health-tech partnerships—highlighted by collaborations with Ultrahuman, a global IoT player, and a CRO-backed AI sleep apnea validation study—even as subscriber attrition pulled net sales down 5.2% and trimmed operating margin to 26.6%, prompting a proposed dividend of SEK 0.53 per share to reassure investors.
The most recent analyst rating on (SE:SLEEP) stock is a Buy with a SEK28.00 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.
The UK Health Security Agency (UKHSA) and Sleep Cycle have launched a 12-week research collaboration to assess whether anonymised, privacy-preserved data from the Sleep Cycle app and its Cough Radar tool can complement traditional respiratory disease surveillance in England. By comparing sleep-based signals, such as nighttime coughing intensity, against existing hospital and surveillance data for respiratory viruses including influenza, RSV and Covid-19, UKHSA aims to determine if sleep app data can provide earlier warning of rising infection rates. The project marks UKHSA’s first systematic evaluation of sleep app data for national epidemiological monitoring and underscores Sleep Cycle’s strategic evolution from a consumer-focused app to a contributor to population-level health research, potentially enhancing early-warning capabilities and demonstrating the value of responsibly used digital health data for public benefit.
The most recent analyst rating on (SE:SLEEP) stock is a Buy with a SEK28.00 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.
Sleep Cycle has signed an agreement with a leading US clinical research organization to run the validation phase of its clinical study for an AI-based sleep apnea screening tool, as the development phase, based on roughly 300 recorded nights, nears completion in the first quarter of 2026 and the full study is scheduled to conclude in September 2026. By shifting validation to the US, the company aims to build a robust, single-country clinical dataset to support regulatory approval, accelerate commercialization and strengthen its positioning in both consumer health and B2B partnerships in a market where sleep apnea is widely underdiagnosed and home-based sleep testing already exceeds SEK 10 billion, with the SEK 30 million validation investment to be capitalized as a development cost and detailed further in the upcoming year-end report.
The most recent analyst rating on (SE:SLEEP) stock is a Buy with a SEK28.00 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.
Sleep Cycle AB will present its year-end report for 2025 via an English-language webcast on 4 February at 09:30 CET, with CEO Erik Jivmark and CFO & Head of IR Elisabeth Hedman leading the presentation followed by a Q&A session for shareholders, media and other stakeholders. The company will publish the interim year-end report earlier that morning at 07:30 CET on its investor website, underscoring its efforts to maintain transparent communication with the market and provide investors and partners with timely insight into its financial performance and strategic progress in the fast-growing sleep technology space.
The most recent analyst rating on (SE:SLEEP) stock is a Buy with a SEK28.00 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.
Sleep Cycle has signed a strategic multi-year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to embed Sleep Cycle’s patented audio-based sleep-tracking analysis directly into its hardware products. The deal advances Sleep Cycle’s ‘Powered by Sleep Cycle’ strategy by extending its technology beyond mobile phones into connected devices, bolstering its technology licensing business and diversifying revenue streams. Management frames the agreement as a key step in scaling the company’s AI-driven sleep technology to broader audiences and positioning Sleep Cycle within the fast-growing market for ambient AI-powered hardware that adapts to health-related biological indicators such as sleep and respiration, with implications for stronger industry positioning and new partnership-driven growth.
The most recent analyst rating on (SE:SLEEP) stock is a Hold with a SEK24.50 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.
Sleep Cycle has launched Luma, an AI-powered health coach that extends beyond traditional sleep tracking to offer personalized guidance connecting sleep to various life goals such as mental health, stress, and productivity. Luma represents a significant expansion in Sleep Cycle’s role, positioning the company as a leader at the intersection of sleep science, AI, and personal guidance, with its availability starting for iOS users and a broader rollout planned for early 2026.
The most recent analyst rating on (SE:SLEEP) stock is a Hold with a SEK24.50 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.
Sleep Cycle has announced a new partnership with Urban Sports Club, a leading sports and wellness platform, to offer an integrated wellness experience by combining sleep insights with fitness goals. This collaboration aims to enhance user health by integrating sleep intelligence into broader wellness ecosystems, potentially driving subscriber and revenue growth for Sleep Cycle.
The most recent analyst rating on (SE:SLEEP) stock is a Hold with a SEK24.50 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.